by Truveta staff | Aug 4, 2025 | Data
Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones. Understanding treatment discontinuation is essential for improving therapy design, informing...
by Truveta Research | Jul 24, 2025 | Research
Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
by Truveta Research | Jul 23, 2025 | Research, Research Insights
The rate of pediatric fluoride prescriptions per all prescriptions decreased by 54.3% from the first quarter of 2022 (5.0 per 1,000 prescriptions) to the second quarter of 2025 (2.3 per 1,000 prescriptions). Across the study period, the 10 US states with lowest...
by Truveta Research | Jul 16, 2025 | Research, Research Insights
The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting evolving clinical guidelines. Use of oral and injectable therapies showed a gradual decline...
by Truveta staff | Jul 9, 2025 | Research
This post kicks off our new series, Truveta experts— a spotlight on the data scientists, researchers, clinicians, and analysts working behind the scenes to drive healthcare research forward with real-world data. Our first contributor is Mantas Dmukauskas, PhD, a...
